Pricing Log in Create free account
Saturday 17 October 2026 Export IPHA’s income statement to Excel — free account

Innate Pharma S.A. Sponsored ADR

IPHA Healthcare Biotechnology

Innate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.

1.43 0.05 −3.38%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
0/9
Altman Z
−11.24
Beneish M
1.14
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 62.08%

Capital & Financial Ratios $m

Market Cap 165.32
Revenue 93.42
Net Income (156.22)
Free Cash Flow (127.75)
Net Debt 10.82
Current Ratio 0.60 (below 1: weak)
Debt/Equity (0.50) (negative: negative equity)
P/E ratio 0.00
Fwd P/E —
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 73.31% (at or above 15%: strong)
Next Y EPS Growth 14.38%
Next Y revenue growth —
Next 5Y EPS Growth 10.08%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.1×, against a ten-year median of −0.6×; over the ten years it ranged from −1.3× in 2021 to 0.1× in 2026.

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 100 87 39 13
Receivables 60 5 14 10
Inventory — — — —
Other — — — —
160 93 53 23
2023 2024 2025 Q'26
Payables 18 17 17 13
ST’ Debt 10 9 10 13
Other 8 8 11 12
43 36 41 38

Compound Annual Growth %

10y 5y 3y
Sales — (33.86%) (44.86%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 10
’24 — — — — 22
’23 — — — — 67
’22 — — — — 61
’21 — — — — 29
’20 — — — — 80
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (60)
’24 — — — — (7)
’23 — — — — (35)
’22 — — — — (20)
’21 — — — — (69)
’20 — — — — (59)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — (25) — — —
’25 — (35) — (60) (60)
’24 — 3 — (8) (8)
’23 — (13) — (35) (38)
’22 — 1 — (21) (21)
’21 — (38) — (70) (71)
’20 — (64) — (60) (72)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (0.62)
’24 — — — — (0.66)
’23 — — — — (0.10)
’22 — — — — (0.77)
’21 — — — — (0.78)
’20 — — — — (0.93)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 5.61 3.30 3.02 1.90 1.81 1.29 1.60

Analyst estimates 2026–2028

Powerpack
High — — — 6.75 8.24 11.95 4.87 3.97 3.51 2.63
People
People Employees — — 157 235 245 215 211 179 181 163
Revenue/emp, $m 0.00 0.00 0.71 0.41 0.33 0.14 0.29 0.37 0.12 0.06
Income, $m
Income, $m Revenue 59 39 111 96 80 29 61 67 22 10
Gross margin, % 0.00 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT 4 (72) 3 (23) (73) (54) (61) (8) (54) (56)
EBT margin, % 6.87 (182.09) 2.89 (24.19) (90.82) (184.10) (100.52) (12.28) (245.87) (546.11)
Net income 13 0 4 (23) (73) (62) (61) (8) (54) (56)
Depreciation 3 5 9 19 65 5 48 6 2 2
Per share, $
Per share, $ Revenue 1.10 0.72 1.89 1.44 1.02 0.37 0.76 0.83 0.27 0.11
Earnings 0.24 (1.07) 0.06 (0.35) (0.93) (0.78) (0.77) (0.10) (0.66) (0.62)
Cash flow (0.72) (1.04) (0.65) 0.58 (0.75) (0.87) (0.25) (0.44) (0.09) (0.67)
Capex 0.00 0.00 (0.03) (1.09) (0.16) (0.02) (0.01) (0.03) (0.01) 0.00
Free cash flow (0.72) (1.04) (0.68) (0.51) (0.91) (0.89) (0.27) (0.47) (0.10) (0.67)
Book value 1.68 1.91 3.36 3.64 2.26 1.60 0.72 0.70 0.12 (0.27)
Shares, m 54 54 59 67 79 80 80 80 81 90
Valuation, ×
Valuation, × P/E 9.81 9.81 9.81 196.94 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/B 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales 0.00 0.00 0.00 0.00 (1.04) (1.10) (0.94) (0.61) (0.58) (0.14)
EV/FCF 0.00 0.00 0.00 0.00 7.31 0.38 0.49 0.83 1.01 0.13
Cash, $m
Cash, $m Operating cash flow (39) (56) (38) 39 (59) (69) (20) (35) (7) (60)
Capex (10) (7) (2) (73) (13) (2) (1) (2) 0 0
Free cash flow (39) (56) (40) (34) (72) (71) (21) (38) (8) (60)
Balance, $m
Balance, $m Working capital 162 77 145 130 146 69 104 117 57 11
Total debt 4 6 5 21 22 52 45 43 34 26
Net debt (204) (134) (193) (224) (151) (89) (62) (57) (54) (13)
Shareholders’ equity 91 104 198 244 178 127 57 56 10 (25)
Returns, %
Returns, % ROA 4.41 (39.34) 0.87 (4.73) (18.26) (18.72) (22.86) (3.92) (33.51) (58.22)
ROIC 0.00 0.00 76.02 (97.88) (165.62) (93.83) 0.00 0.00 0.00 0.00
ROE 13.70 (60.02) 2.39 (10.54) (34.67) (40.93) (66.48) (14.47) (162.88) 742.02
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025

Charts ten years each

Innate Pharma S.A. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ORMP Oramed Pharmaceuticals Inc. $173.9M 1.0× — (loss-making) +193.26% (above 0%: growing) +493.75% (above 0%: growing) +94.29% (above 0%: growing) 0.65% 0.00% Compare
WHWK Whitehawk Therapeutics, Inc. $173.3M — (loss-making) — (loss-making) +33.48% (above 0%: growing) n/m +72.57% (above 0%: growing) 89.36% 0.00% Compare
DTIL Precision BioSciences, Inc. $170.3M — (loss-making) — (loss-making) +37,272.41% (above 0%: growing) n/m +33.73% (above 0%: growing) 100.00% 0.00% Compare
IPHA Innate Pharma S.A. Sponsored ADR $165.3M — (loss-making) — +246.29% (above 0%: growing) +106.08% (above 0%: growing) −929.03% (below 0%: shrinking) 0.00% 0.00%
CHRS Coherus Oncology, Inc. $165.3M — (loss-making) — (loss-making) +39.53% (above 0%: growing) n/m −33.15% (below 0%: shrinking) 70.35% (225.98%) Compare
VRXA Veraxa Biotech AG $162.5M — — — — — — — Compare
CMPX Compass Therapeutics, Inc. $161.5M — (loss-making) — (loss-making) — n/m −26.05% (below 0%: shrinking) 100.00% 0.00% Compare
ADAG Adagene Inc. Sponsored ADR $161.1M — (loss-making) — (loss-making) — — −11.08% (below 0%: shrinking) — — Compare
MDWD MediWound Ltd. $157.6M — (loss-making) — (loss-making) −45.83% (below 0%: shrinking) n/m −49.90% (below 0%: shrinking) 10.90% (305.89%) Compare
Median of peers $163.9M — — +39.53% — −11.08% 79.86% 0.00%

All 614 Biotechnology stocks →

Innate Pharma S.A. Sponsored ADR (IPHA) key facts

  • Concern: Innate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.
  • Concern: Innate Pharma S.A. Sponsored ADR reported a net loss of $55.6 million, or a loss of $0.62 per share, for fiscal 2025.
  • Innate Pharma S.A. Sponsored ADR (IPHA) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, IPHA traded at $1.43, a market capitalization of $165.3 million.
  • Return on equity was 742.0% and debt-to-equity -0.50.
  • Its Piotroski F-score is 0 out of 9 and its Altman Z-score is −11.24 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Innate Pharma S.A. Sponsored ADR (IPHA) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IPHA · Data as of Dec 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com